GMAB - Genmab AS - Stock Price & Dividends

Exchange: USA Stocks • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US3723032062

Antibodies, Cancer, Therapeutics, Treatment, Diseases, Medicines

Genmab A/S is a biotechnology company that specializes in developing innovative antibody therapeutics for the treatment of cancer and other diseases. With a strong focus on research and development, the company has established itself as a leader in the field of antibody therapeutics.

Genmab's product portfolio includes DARZALEX, a human monoclonal antibody approved for the treatment of patients with multiple myeloma (MM). The company is also developing teprotumumab for the treatment of thyroid eye disease, and Amivantamab for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC).

In addition to these products, Genmab has a robust pipeline of promising candidates, including daratumumab for the treatment of MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; and DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for treating solid tumors. The company is also developing Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia, as well as HexaBody-CD38 and GEN3017 for treating hematological malignancies.

Genmab has a number of ongoing clinical trials, including Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. The company also has various active pre-clinical programs in development.

Genmab has established several strategic collaborations with leading pharmaceutical and biotechnology companies, including Seagen Inc., argenx, AbbVie, BioNTech, Janssen, and Novo Nordisk A/S. These collaborations enable the company to leverage its expertise in antibody development and accelerate the development of new therapeutic antibodies.

Founded in 1999, Genmab A/S is headquartered in Copenhagen, Denmark, and has established itself as a pioneer in the field of antibody therapeutics. With a strong commitment to innovation and a focus on improving patient outcomes, Genmab is well-positioned to continue making significant contributions to the field of cancer treatment and beyond.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for GMAB - Genmab AS  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for GMAB - Genmab AS  - Stock Price & Dividends

GMAB Stock Overview

Market Cap in USD 14,448m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2009-06-01

GMAB Stock Ratings

Growth 5y -13.6
Fundamental 59.1
Dividend
Rel. Performance vs Sector -7.02
Analysts 3.67/5
Fair Price Momentum 20.06 USD
Fair Price DCF 255.97 USD

GMAB Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

GMAB Growth Ratios

Growth Correlation 3m -91.7%
Growth Correlation 12m -85.4%
Growth Correlation 5y -8.1%
CAGR 5y 0.81%
CAGR/Mean DD 5y 0.04
Sharpe Ratio 12m -1.04
Alpha vs SP500 12m -56.07
Beta vs SP500 5y weekly 0.75
ValueRay RSI 59.31
Volatility GJR Garch 1y 28.37%
Price / SMA 50 -5.37%
Price / SMA 200 -15.18%
Current Volume 1560.5k
Average Volume 20d 1490.4k

External Links for GMAB Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of GMAB stocks?
As of November 10, 2024, the stock is trading at USD 23.08 with a total of 1,560,527 shares traded.
Over the past week, the price has changed by +2.30%, over one month by -2.16%, over three months by -14.74% and over the past year by -25.55%.
What are the forecast for GMAB stock price target?
According to ValueRays Forecast Model, GMAB Genmab AS will be worth about 22.1 in November 2025. The stock is currently trading at 23.08. This means that the stock has a potential downside of -4.42%.
Issuer Forecast Upside
Wallstreet Target Price 39.4 70.7
Analysts Target Price 44.8 94.0
ValueRay Target Price 22.1 -4.42